Anti-depressants and Psychiatric disorders
Depression is the most common psychopathic disease. In 2004, total spending on anti-depression treatment has reached US$44 billion in U.S.
In China, sales of antidepressants amounted to 2 billion in 2004. China Ministry of Public Health has already indicated depression as a key disease which demands more resources for prevention and treatment. Antidepressants in the PRC is still in its inception however, sales has been growing rapidly in recent years as more people are aware of the disease.
Among different categories of anti-depressants, Selective Serotonin Reuptake Inhibitors (SSRIs) occupy an overwhelming share in the PRC.
The group’s first product in this area, Citalopram (西酞普蘭), is expected to be launched in October 2006. While at the same time, the Group is developing a new Serotonin Norepinephrine Reuptake Inhibitors (SNRI) which is expected to be launched in 2007.
Citalopram Hydrobromide (西酞普蘭)
Citalopram Hydrobromide is a Selective Serotonin Reuptake Inhibitor (SSRI). Its main application is to treat depression disorder, including endogenous and exogenous depression. It has the advantage of having the highest selectivity among SSRIs; the product is characterized by its high safety profile, low incidence of side effects as well as broad scope of function and convenient form of in-take.
The product has proven success in the global market with expected growth rate of 10% per year. The group will be among the first to launch this product in China, and is expecting to have SFDA granting an exclusive post-marketing surveillance period of 3 years.
With the efforts of our product development team, we will file a dosage form patent for this prime product.